

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/920,392	08/01/2001	Christos Zouboulis	01895300	4392
	7590 07/06/200 WN, ROWE & MAW	EXAMINER		
71 S. WACKER			LANKFORD JR, LEON B	
CHICAGO, IL 60606			ART UNIT	PAPER NUMBER
			1651	
			MAIL DATE	DELIVERY MODE
		•	07/06/2007	· PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
		09/920,392	ZOUBOULIS, CHRIST	os		
	Office Action Summary	Examiner	Art Unit			
		Leon Lankford	1651			
	The MAILING DATE of this communication app			ss		
Period fo	or Reply		•			
WHIC - Exter after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATES and the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim 17 iiii apply and will expire SIX (6) MONTHS from 18 cause the application to become ABANDONE	J. nely filed the mailing date of this commu D. (35 U.S.C. § 133).			
Status						
1) 🖂	Responsive to communication(s) filed on 21 Au	iaust 2006				
	This action is FINAL . 2b) This action is non-final.					
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
,	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims					
4) 🖂	Claim(s) <u>1-6 8-10 23-25 27-31 33-36 38 40 42</u>	63- 68 39 43 45-62 is/are pendin	g in the application			
	4a) Of the above claim(s) 39 43 45- 62 is/are withdrawn from consideration.					
	Claim(s) is/are allowed.					
6)⊠	☑ Claim(s) 1-6 8-10 23-25 27-31 33-36 38 40 42 63- 68 is/are rejected.					
7)	Claim(s) is/are objected to.					
8) 🗌	Claim(s) are subject to restriction and/or	r election requirement.				
Applicati	on Papers					
9)	The specification is objected to by the Examine	r.				
	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
	Applicant may not request that any objection to the					
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11)	The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-1	152.		
Priority u	ınder 35 U.S.C. § 119					
_	Acknowledgment is made of a claim for foreign All b) Some * c) None of:	priority under 35 U.S.C. § 119(a)	-(d) or (f).			
	1. Certified copies of the priority documents	s have been received.				
	2. Certified copies of the priority documents have been received in Application No					
	3. Copies of the certified copies of the prior	ity documents have been receive	d in this National Sta	ge		
	application from the International Bureau	· · · · · · · · · · · · · · · · · · ·				
* 5	See the attached detailed Office action for a list	of the certified copies not receive	d.			
Attachmen	• •	_				
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da				
2) Notic 3) Infor	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08)	5) 🔲 Notice of Informal P				
Paper No(s)/Mail Date 6) Other:						

DETAILED ACTION

Applicant's arguments filed 8/21/06 have been fully considered but they are not persuasive. The declaration of Christos Zouboulis has been fully considered and is found very persuasive that the invention described therein is novel and unobvious however the claims are still not commensurate in scope with the showing.

Applicant's arguments have been considered however a showing to overcome a prima facie case of obviousness must be clear and convincing(In re Lohr et al. 137 USPQ 548) as well as commensurate in scope with the claimed subject matter (In re Lindner 173 USPQ 356; In re Hyson, 172 USPQ 399 and In re Boesch et al., 205 USPQ 215 (CCPA 1980). Claim 1 does not serve to distinguish over the art since it only requires "features" of sebocytes and applicant's arguments are not persuasive that one wouldn't expect at least some features of the sebocytes to remain after SV40 immortalization and this would seem consistent with the Zouboulis. It is conceivable but not readily apparent that a combination of dependent claims would result in commensurate claims and applicant is invited to combine claims with pointed arguments in response to this action.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-9, 23-38,40-42,44,45, 47 & 63-68 are rejected under 35 U.S.C. 103(a) as beingunpatentable over Zouboulis et al(*Dermatology 196*) or Rosenfield(6004751) in view of Bryan (*Crit Rev Onc 5*(4)).

Zouboulis and Rosenfield teach cell cultures of sebocytes particularly taken from facial sebaceous glands. Zouboulis teaches cell culture of sebocytes dates to at least 1989. The references do not teach that the cells are immortalized, however at the time the invention was made, it would have been obvious to immortalize the sebocytes of Zouboulis and/or Rosenfield because Bryan clearly teaches that cells in culture can be immortalized by SV40 and motivates one of ordinary skill in the art to do so because of the obvious advantages for study of having a cell line which does not die off. The method is not exclusive to Bryan and has been done for decades in scores of cell types. Given the breadth and success in the art of immortalization via SV40 (and other known immortalization techniques), there was clearly a reasonable expectation of success for one of ordinary skill in the art at the time the invention was made to make an immortalized human sebocyte cell line. It follows that the immortalized cell line, *per se*, would have been obvious at the time the invention was made.

Accordingly, the claimed invention was prima facie obvious to one of ordinary skill in the art at the time the invention was made especially in the absence of evidence to the contrary.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leon Lankford whose telephone number is 571-272-0917. The examiner can normally be reached on Mon-Thu 7:30-6.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Leon Lankford Primary Examiner Art Unit 1651

LBL